5 November 2023
RNZ's Kim Hill discusses the results of the Malaghan Institute's phase 1 clinical trial.
Michele Leggott / Dr Robert Weinkove / Prof Carl June
Results have been released for Malaghan Institute's ground-breaking CAR T-cell cancer therapy trial, and they are promising.
The therapy reprogrammes a patient's own immune cells to recognise and kill cancer.
Discussing the treatment and trial are Professor Carl June from the University of Pennsylvania who pioneered the therapy and Dr Robert Weinkove, who leads Malaghan's CAR T-cell programme.
They are joined by writer and poet Michele Leggott, who is twelve months into the trial, for an update on her progress.
Related articles
In Focus: CAR T-cell therapy, the battle of the blood cells
26 September 2024
Read more
In Focus: CAR T-cell therapy, the battle of the blood cells
26 September 2024
Read more
Phase 2 clinical trial underway to confirm effectiveness and safety of NZ’s first CAR T-cell cancer therapy
23 July 2024
Read more
Phase 2 clinical trial underway to confirm effectiveness and safety of NZ’s first CAR T-cell cancer therapy
23 July 2024
Read more
RNZ Our Changing World: Targeting bacteria, and health inequities
4 July 2024
Read more
New clinical research aims to reduce stomach cancer rates and disparities in New Zealand
28 May 2024
Read more